Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
DCF Valuation
Base-case fair value
$133.38
Intrinsic $177.85 · 25% MOS
Current price: $132.84
Base-case summary
Our base-case DCF for AstraZeneca PLC (AZN.XLON) projects 10 years of free cash flow growth at 15.5% for years 1–5 and 7.8% for years 6–10, anchored to 15.5% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $7.7B in trailing free cash flow, this produces an intrinsic value of $177.85 per share. A 25% safety margin gives a fair value of $133.38, suggesting the stock is currently 0% undervalued against the $132.84 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$7.7B
Cash & equivalents
$5.7B
Total debt
$29.1B
Shares outstanding
1.6B